In today’s briefing:
- SUMCO (3436 JP): CEO Describes Tight Supply, Rising Prices
- Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback
SUMCO (3436 JP): CEO Describes Tight Supply, Rising Prices
- CEO Hashimoto told the Nikkei newspaper that customers are ordering silicon wafers at higher prices before they are made, even as production capacity is being increased.
- SEMI and TSMC announcements point to rising wafer demand for at least another two years. SUMCO’s expansion plans suggest at least three years.
- We continue to recommend buying into the current weakness for the medium to long term.
Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback
- Green Cross (006280 KS) is currently waiting for marketing approval from the FDA for its immune globulin intravenous injection, which will mark its entry into the U.S. market.
- The company will start commercializing its hemophilia A treatment, GreenGene F in China market this year. As a third-generation product, GreenGene is expected to gain substantial market share.
- Green Cross shares remained subdued last year, as the company could not finalize a contract manufacturing deal for COVID-19 vaccine.
Related tickers: SUMCO Corp (3436.T), Green Cross (006280.KS)
Before it’s here, it’s on Smartkarma
